These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 33823168)

  • 21. Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting.
    Carey N; Leahy J; Trela-Larsen L; Mc Cullagh L; Barry M
    J Mark Access Health Policy; 2023; 11(1):2166375. PubMed ID: 36684853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
    Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
    Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
    Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
    JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
    Lin JK; Lerman BJ; Barnes JI; Boursiquot BC; Tan YJ; Robinson AQL; Davis KL; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2018 Nov; 36(32):3192-3202. PubMed ID: 30212291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
    Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
    J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
    Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
    J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain.
    Ribera Santasusana JM; de Andrés Saldaña A; García-Muñoz N; Gostkorzewicz J; Martínez Llinàs D; Díaz de Heredia C
    Clinicoecon Outcomes Res; 2020; 12():253-264. PubMed ID: 32523362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.
    Bastos-Oreiro M; de Las Heras A; Presa M; Casado MA; Pardo C; Martín-Escudero V; Sureda A
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
    Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
    J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
    Goto H; Makita S; Kato K; Tokushige K; Fujita T; Akashi K; Izutsu K; Teshima T
    Int J Clin Oncol; 2020 Sep; 25(9):1736-1743. PubMed ID: 32448949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
    Matasar M; Masaquel A; S Ho R; Launonen A; Ng CD; Wang R; Fox D; Hossain F; Li J; Burke JM
    J Med Econ; 2023; 26(1):1134-1144. PubMed ID: 37674384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
    Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
    Future Oncol; 2024; 20(19):1333-1349. PubMed ID: 38597742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
    Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
    Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
    Patel KK; Isufi I; Kothari S; Foss F; Huntington S
    Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
    Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
    J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of polatuzumab-bendamustine-rituximab
    Calamia M; McBride A; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.